# Should non-invasive prenatal testing be recommended for patients who achieve pregnancy with PGT?

**Authors:** Yunhao Liang, Meiyi Li, Jia Fei, Zhiheng Chen

PMC · DOI: 10.1186/s12884-024-06284-7 · 2024-02-01

## TL;DR

The study explores whether non-invasive prenatal testing can replace invasive testing after preimplantation genetic testing in pregnancies.

## Contribution

It provides evidence that non-invasive testing is a viable alternative to invasive testing in PGT cycles.

## Key findings

- Non-invasive testing showed similar clinical outcomes to invasive testing in PGT patients.
- Patients in the non-invasive group were older on average but had comparable pregnancy results.
- Non-invasive testing is suitable for PGT but has limited effectiveness in PGT-M cases.

## Abstract

To determine whether non-invasive prenatal testing is an alternative testing option to preimplantation genetic testing (PGT) in pregnant patients.

This was a retrospective study of the clinical outcomes of patients who underwent PGT and invasive or non-invasive pregnancy testing after euploid blastocyst transfer at our IVF centre between January 2017 and December 2022.

In total, 321 patients were enrolled in this study, 138 (43.0%) received invasive pregnancy testing, and 183 (57.0%) patients underwent non-invasive testing. The mean age of the patients in Group 2 was higher than that of the patients in Group 1 (35.64 ± 4.74 vs. 31.04 ± 4.15 years, P < 0.001). The basal LH and AMH levels were higher in Group 1 than in Group 2 (4.30 ± 2.68 vs. 3.40 ± 1.88, P = 0.003; 5.55 ± 11.22 vs. 4.09 ± 3.55, P = 0.012), but the clinical outcomes were not significantly different. Furthermore, the clinical outcomes of patients undergoing invasive testing were similar to those of patients undergoing non-invasive testing with the same PGT indication.

Our results suggest that non-invasive pregnancy testing is a suitable alternative option for detecting the foetal chromosomal status in a PGT cycle. However, the usefulness of non-invasive testing in PGT-M patients is still limited.

## Full-text entities

- **Genes:** AMH (anti-Mullerian hormone) [NCBI Gene 268] {aka MIF, MIS}
- **Diseases:** chromosomal or genetic disease (MESH:D040181), monogenic disease (MESH:D004194), CNVs (MESH:D000092342), Preterm (MESH:D047928), PGT-A (MESH:D000782), IVF (MESH:C537182), Congenital anomalies (MESH:D000013), PGT (MESH:D013736), abortion (MESH:D000026), trisomy 13 (MESH:D000073839), sex chromosome abnormalities (MESH:D012729), monosomy X (MESH:D014424), CVS (MESH:C564876), limb defects (MESH:C537754), trisomy 21 (MESH:D004314), genetic abnormalities (MESH:D030342), trisomy 18 (MESH:D000073842), miscarriage (MESH:D000022), IPT (MESH:C537770), chromosomal abnormalities (MESH:D002869), birth defect (MESH:D000014)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC10832195/full.md

---
Source: https://tomesphere.com/paper/PMC10832195